A naukri.com initiative
Bioengineer
1w
391
Image Credit: Bioengineer
Safety and Quality of CDK4/6 Inhibitors
- A multicenter study in China explored the safety and quality of life for patients undergoing CDK4/6 inhibitor therapy for advanced breast cancer.
- CDK4/6 inhibitors have transformed treatment for HR+, HER2- breast cancer by impeding cell cycle progression.
- Over 1,200 patients were surveyed, revealing insights into treatment efficacy, adverse effects, and patient experiences.
- The study highlighted common hematologic toxicities like leukopenia and neutropenia among patients on CDK4/6 inhibitors.
- Fatigue was a prevalent side effect, impacting over one-third of respondents, along with alopecia and weakness.
- Differences in alopecia rates were noted among patients receiving different CDK4/6 inhibitors.
- Quality of life analyses showed variations between treatments, with palbociclib potentially affecting breast symptoms differently than abemaciclib.
- Alopecia correlated with body image, systemic therapy side effects, and psychological distress, emphasizing its broader impact.
- The study underscores the need for personalized treatment strategies that consider patient-reported outcomes and quality of life.
- Routine quality of life assessments and proactive symptom management are essential for enhancing patient experience and treatment satisfaction.
Read Full Article
23 Likes
For uninterrupted reading, download the app